PURPOSE: A correlation of treatment for uterine sarcoma with outcome, prognostic importance of pathology, and clinical parameters. PATIENTS AND METHODS: One hundred forty-one patients (median age: 56 years, range: 19-85 years) with a histologically verified uterine sarcoma were identified from a database compiled at the Royal Marsden Hospital and the University of Florence between 1974 and 2001. Seventy-two patients had leiomyosarcoma, 42 had mixed müllerian tumors, 22 had endometrial stromal sarcoma, 1 hemangiopericytoma, 1 rhabdomyosarcoma, and 3 patients had unspecified sarcoma. According to FIGO classification, Stage I, II, III, and IV tumors were identified in 71, 13, 31, and 26 patients, respectively. RESULTS: At the time of analysis, 73.7% of patients were dead, and 26.3% were alive with a median survival of 2 years from initial diagnosis. Univariate analysis for cause-specific survival demonstrated statistical significance for histology (p = 0.02), grade (p = 0.003), stage (p = 0.007), and age (p = 0.02). Multivariate analysis demonstrated significant prognostic values for stage (p = 0.02) and histology (p = 0.05) only. Postoperative radiotherapy with a total dose higher than 50 Gy seems to be significant (p = 0.001) in reducing local recurrence. CONCLUSIONS: Our data favor treatment for Stages I, II, and III of uterine sarcoma with radical surgery plus radical dose irradiation comprising both external beam radiotherapy and brachytherapy.
PURPOSE: A correlation of treatment for uterine sarcoma with outcome, prognostic importance of pathology, and clinical parameters. PATIENTS AND METHODS: One hundred forty-one patients (median age: 56 years, range: 19-85 years) with a histologically verified uterine sarcoma were identified from a database compiled at the Royal Marsden Hospital and the University of Florence between 1974 and 2001. Seventy-two patients had leiomyosarcoma, 42 had mixed müllerian tumors, 22 had endometrial stromal sarcoma, 1 hemangiopericytoma, 1 rhabdomyosarcoma, and 3 patients had unspecifiedsarcoma. According to FIGO classification, Stage I, II, III, and IV tumors were identified in 71, 13, 31, and 26 patients, respectively. RESULTS: At the time of analysis, 73.7% of patients were dead, and 26.3% were alive with a median survival of 2 years from initial diagnosis. Univariate analysis for cause-specific survival demonstrated statistical significance for histology (p = 0.02), grade (p = 0.003), stage (p = 0.007), and age (p = 0.02). Multivariate analysis demonstrated significant prognostic values for stage (p = 0.02) and histology (p = 0.05) only. Postoperative radiotherapy with a total dose higher than 50 Gy seems to be significant (p = 0.001) in reducing local recurrence. CONCLUSIONS: Our data favor treatment for Stages I, II, and III of uterine sarcoma with radical surgery plus radical dose irradiation comprising both external beam radiotherapy and brachytherapy.
Authors: Youssef Benabdejlil; Mohammed Elmarjany; Abdellah Babahabib; Mehdi Elhassani; Hafsa Chahdi; Jaouad Kouach; Driss Rahali Moussaoui; Mohammed Dehayni Journal: Pan Afr Med J Date: 2014-09-24
Authors: R Rothmund; M Huebner; C Joachim; A Hartkopf; T Fehm; M Bamberg; M Wallwiener; S Brucker; F A Taran Journal: Geburtshilfe Frauenheilkd Date: 2011-12 Impact factor: 2.915
Authors: Shirish M Gadgeel; Linda C Harlan; Christopher A Zeruto; Michael Osswald; Ann G Schwartz Journal: Cancer Date: 2009-06-15 Impact factor: 6.860
Authors: Alessandra Franzetti Pellanda; Berardino De Bari; Elisabeth Deniaud-Alexandre; Marco Krengli; Paul Van Houtte; Antonella Richetti; Salvador Villà; Hadassah Goldberg; Ewa Szutowicz-Zielińska; Michel Bolla; Heidi Rutten; Marc Van Eijkeren; Philip Poortmans; Guido Henke; Yavuz Anacak; Steve Chan; Christine Landmann; Carine Kirkove; Luciano Scandolaro; Jacques Bernier; René-Olivier Mirimanoff; Mahmut Ozsahin Journal: Chin J Cancer Res Date: 2017-12 Impact factor: 5.087